ESMO 2018 | New data from the PACIFIC trial for NSCLC

Marina Garassino, MD, of the National Cancer Institute of Milan, Milan, Italy, highlights that this year was not only the year of combination therapy for non-small lung cancer (NSCLC), but also the year of advances in the treatment of stage 3 disease. Dr Garassino reminds us of last year’s PACIFIC trial (NCT02125461), stating that this year has finally produced data on overall survival. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.